Recent advances in positron emission tomography (PET) radiotracers for imaging phosphodiesterases

Current Topics in Medicinal Chemistry

Volumn 12, Issue 11, 2012, Pages 1224-1236

  Andrés, José Ignacio ^a   de Angelis, Meri ^a   Alcázar, Jesús ^a   Celen, Sofie ^b   Bormans, Guy ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

3',5' Cyclic adenosine monophosphate (cAMP); 3',5' cyclic guanosine monophosphate (cGMP); Imaging; Inhibitor; PET; Phosphodiesterase (PDE); Radioligand

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE C 11; CARBON 11; COPPER 64; CYCLIC AMP; CYCLIC GMP; FLUORINE 18; G PROTEIN COUPLED RECEPTOR; GALLIUM 68; IODINE 124; NITROGEN 13; OXYGEN 15; PAPAVERINE; PAPAVERINE C 11; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; RAL 01; RBQ 08; ROLIPRAM; ROLIPRAM C 11; TP 10; UNCLASSIFIED DRUG; VARDENAFIL; ZIRCONIUM; ZIRCONIUM 89;

ARTICLE; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SECOND MESSENGER;

EID: 84861739410     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612800672853     Document Type: Article

References (111)

1. 13N radiolabels for positron emission tomography. Angew. Chem. Int. Ed. Engl., 2008, 47, 8998-9033.
2. Pysz, M.A.; Gambhir, S.S.; Willmann, J.K. Molecular imaging: current status and emerging strategies. Clin. Radiol., 2010, 65, 500-516.
3. Zaidi, H.; Del Guerra, A. An outlook on future design of hybrid PET/MRI systems. Med. Phys., 2011, 38, 5667-5689.
4. Serdons, K.; Verbruggen, A.; Bormans, G.M. Developing new molecular imaging probes for PET. Methods, 2009, 48, 104-111.
5. ICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. http://www.emea.europa.eu/docs/en_GB/document_library/Scientif ic_guideline/2009/09/WC500002720.pdf
6. Hargreaves, R.J. The role of molecular imaging in drug discovery and development. Clin. Pharmacol. Ther., 2008, 83, 349-353.
7. Molecular Imaging and Contrast Agent Database (MICAD). http://www.ncbi.nlm.nih.gov/books/NBK5330/
8. Bender, A.T.; Beavo, J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev., 2006, 58, 488-520.
9. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol. Ther., 2006, 109, 366-398.
10. Omori, K.; Kotera, J. Overview of PDEs and their regulation. Circulation Res., 2007, 100, 309-327.
11. Conti, M.; Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem., 2007, 76, 481-511.
12. Conti, M. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol. Endocrinol., 2000, 14, 1317-1327.
13. Soderling, S.H.; Beavo, J.A. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol., 2000, 12, 174-179.
14. Mehats, C.; Andersen, C.B.; Filopanti, M.; Jin, S.L.; Conti, M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol. Metab., 2002, 13, 29-35.
15. Dent G.; White, S.R.; Tenor, H.; Bodtke, K.; Schudt, C.; Leff, A.R.; Magnussen, H.; Rabe, K.F. Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Pulm. Pharmacol. Ther., 1998, 11, 47-56.
16. Sonnenburg, W.K.; Rybalkin, S.D.; Bornfeldt, K.E.; Kwak, K.S.; Rybalkina, I.G.; Beavo, J.A. Identification, quantitation, and cellular localization of PDE1 calmodulin-stimulated cyclic nucleotide phosphodiesterases. Methods, 1998, 14, 3-19.
17. Van Staveren, W.C.; Steinbusch, H.W.; Markerink-Van Ittersum, M.; Repaske, D.R.; Goy, M.F.; Kotera, J.; Omori, K.; Beavo, J.A.; De Vente, J. mRNA expression patterns of the cGMPhydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J. Comp. Neurol., 2003, 467, 566-580.
18. Yanaka, N.; Kurosawa, Y.; Minami, K.; Kawai, E.; Omori, K. cGMP-phosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles. Biosci. Biochem., 2003, 67, 973-979.
19. Coudray, C.; Charon, C.; Komas, N.; Mory, G.; Diot-Dupuy, F.; Manganiello, V.; Ferre. P.; Bazin, R. Evidence for the presence of several phosphodiesterase isoforms in brown adipose tissue of Zucker rats: modulation of PDE2 by the fa gene expression. FEBS Lett., 1999, 456, 207-210.
20. Reinhardt, R.R.; Chin, E.; Zhou, J.; Taira, M.; Murata, T.; Manganiello, V.C.; Bondy, C.A. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J. Clin. Invest., 1995, 95, 1528-1538.
21. Cheung, P.P.; Xu, H.; McLaughlin, M.M.; Ghazaleh, F.A.; Livi, G.P.; Colman, R.W. Human platelet cGI-PDE: expression in yeast and localization of the catalytic domain by deletion mutagenesis. Blood, 1996, 88, 1321-1329.
22. Wechsler, J.; Choi, Y.H.; Krall, J.; Ahmad, F.; Manganiello, V.C.; Movsesian, M.A. Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J. Biol. Chem., 2002, 277, 38072-38078.
23. Shakur, Y.; Holst, L.S.; Landstrom, T.R.; Movsesian, M.; Degerman, E.; Manganiello, V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog. Nucleic Acid Res. Mol. Biol., 2001, 66, 241-277.
24. Houslay, M.D.; Sullivan, M.; Bolger, G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol., 1998, 44, 225-342.
25. Perez-Torres. S.; Miro, X.; Palacios, J.M.; Cortes, R.; Puigdomenech, P.; Mengod, G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J. Chem. Neuroanat., 2000, 20, 349-374.
26. Richter, W.; Jin, S.L.; Conti, M. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem. J., 2005, 388, 803-811.
27. Giordano, D.; De Stefano, M.E.; Citro, G.; Modica, A.; Giorgi, M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim. Biophys. Acta, 2001, 1539, 16-27.
28. Kotera, J.; Fujishige, K.; Omori, K. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J. Histochem. Cytochem., 2000, 48, 685-693.
29. Pauvert, O.; Lugnier, C.; Keravis, T.; Marthan, R.; Rousseau, E.; Savineau, J.P. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. Br. J. Pharmacol., 2003, 139, 513-522.
30. Stryer, L. Vision: from photon to perception. Proc. Natl. Acad. Sci. USA, 1996, 93, 557-559.
31. Morin, F.; Lugnier, C.; Kameni, J.; Voisin, P. Expression and role of phosphodiesterase 6 in the chicken pineal gland. J. Neurochem., 2001, 78, 88-99.
32. Bloom, T.J.; Beavo, J.A. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. Sci. USA, 1996, 93, 14188-14192.
33. Miro, X.; Perez-Torres, S.; Palacios, J.M.; Puigdomenech, P.; Mengod, G. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse, 2001, 40, 201-214.
34. Hayashi, M.; Matsushima, K.; Ohashi, H.; Tsunoda, H.; Murase, S.; Kawarada, Y.; Tanaka, T. Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun., 1998, 250, 751-756.
35. Wang, P.; Wu, P.; Egan, R.W.; Billah, M.M. Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution. Gene, 2001, 280, 183-194.
36. Soderling, S.H.; Bayuga, S.J.; Beavo, J.A. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc. Natl. Acad. Sci. USA, 1998, 95, 8991-8996.
37. Fisher, D.A.; Smith, J.F.; Pillar, J.S.; St Denis, S.H.; Cheng, J.B. Isolation and characterization of PDE9A, a novel human cGMPspecific phosphodiesterase. J. Biol. Chem., 1998, 273, 15559-15564.
38. Andreeva, S.G.; Dikkes, P.; Epstein, P.M.; Rosenberg, P. A. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J. Neurosci., 2001, 21, 9068-9076.
39. Wang, P.; Wu, P.; Egan, R.W.; Billah, M.M. Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. Gene, 2003, 314, 15-27.
40. Soderling, S.H.; Bayuga, S.J.; Beavo, J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. USA, 1999, 96, 7071-7076.
41. Fujishige, K.; Kotera, J.; Michibata, H.; Yuasa, K.; Takebayashi, S.; Okumura, K.; Omori, K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem., 1999, 274, 18438-18445.
42. Loughney, K., Snyder, P.B.; Uher, L.; Rosman, G.J.; Ferguson, K.; Florio, V. A. Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide. Gene, 1999, 234, 109-117.
43. Fawcett, L.; Baxendale, R.; Stacey, P.; McGrouther, C.; Harrow, I.; Soderling, S.; Hetman, J.; Beavo, J.A.; Phillips, S.C. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc. Natl. Acad. Sci. USA, 2000, 97, 3702-3707.
44. Yuasa, K.; Kotera, J.; Fujishige, K.; Michibata, H.; Sasaki, T.; Omori, K. Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J. Biol. Chem., 2000, 275, 31469-3147.
45. Houslay, M.D.; Schafer, P.; Zhang, K.Y. Keynote review: phosphodiesterase-4 as therapeutic target. Drug Discov. Today, 2005, 10, 1503-1519.
46. Galie, N.; Ghofrani, H.A.; Torbicki, A.; Barst, R.J.; Rubin, L.J.; Badesch, D.; Fleming, T.; Parpia, T.; Burgess, G.; Branzi, A.; Grimminger, F.; Kurzyna, M.; Simonneau, G. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med., 2005, 353, 2148-2157.
47. Lee, A.J.; Chiao, T.B.; Tsang, M.P. Sildenafil for pulmonary hypertension. Ann. Pharmacother., 2005, 39, 869-884.
48. Reneerkens, O.A.H.; Rutten, K.; Steinbusch, H.W.M.; Blokland, A.; Prickaerts, J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology, 2009, 202, 419-443.
49. Savai, R.; Savai Pullamsetti, S.; Banat, G-A.; Wiessmann, N.; Ghofrani, H.A.; Grimminger, T.; Schermuly, R.T. Targeting cancer with phosphodiesterase inhibitotors. Expert Opin. Investig. Drugs, 2010, 19, 117-131.
50. Medina, A. E. Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions. Frontiers Neurosci., 2011, 5, 21.
51. Chen, R.W.; Williams, A.J.; Liao, Z.; Yao, C.; Tortella, F.C.; Dave, J.R. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci. Lett., 2007, 418, 165-169.
52. Laddha, S.S.; Bhatnagar, S.P. A new therapeutic approach in Parkinson's disease: Some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents. Bioorg. Med. Chem., 2009, 17, 6796-6802.
53. Kakkar, R.; Raju, R.V.S.; Sharma, R.K. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell. Mol. Life Sci., 1999, 55, 1164-1186.
54. Menniti, F.S.; Faraci, W.S.; Schmidt, C.J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov., 2006, 5, 660-670.
55. Lakics, V.; Karran, E.H.; Boess, F.G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology, 2010, 59, 367-374.
56. Schermuly, R.T.; Pullamsetti, S.S.; Kwapiszewska, G.; Dumitrascu, R.; Tian, X.; Weissmann, N.; Ghofrani, H.A.; Kaulen, C.; Dunkern, T.; Schudt, C.; Voswinckel, R.; Zhou, J.; Samidurai, A.; Klepetko, W.; Paddenberg, R.; Kummer, W.; Seeger, W.; Grimminger, F. Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension. Circulation, 2007, 115, 2331-2339.
57. Mates, S.; Fienberg, A.A. Organic Compounds. PCT Int. Appl. WO2008063505, May 29, 2008.
58. Fienberg, A.A.; Wennogle, L.J.; Mates, S. Organic Compounds. PCT Int. Appl. WO2010132127, November 18, 2010.
59. Li, P.; Wennogle, L.P.; Zhao, J.; Zheng, H. Phosphodiesterase 1-Targeting Tracers and Methods. PCT Int. Appl. WO2011043816, April 14, 2011.
60. 11C]rolipram and positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 1680-1683.
61. 11C]rolipram: comparison of two-dimensional planar, bisected and quadrisected image analyses. Nucl. Med. Biol., 2008, 35, 493-500.
62. Kenk, M.; Thomas, A.; Lortie, M.; deKemp, R.; Beanlands, R. S.; DaSilva, N. J. PET measurement of cAMP-mediated phosphodiesterase-4 with (R)-[11C]Rolipram. Curr. Radiopharmaceuticals, 2011, 4, 44-58.
63. DaSilva, J.N.; Valente, C.M.; Wilson, A.A.; Warsh, J.J.; Houle, S. Carbon-11 labeling of the selective inhibitors of phosphodiesterase-IV Ro-20-1724 and rolipram. J. Label. Compd. Radiopharm., 1997, 40, 678-680.
64. Houslay, M.D.; Scotland, G.; Erdogan, S.; Huston, E.; Mackenzie, S.; McCallum, J.F.; McPhee, I.; Pooley, L.; Rena, G.; Ross, A.; Beard, M.; Peder, A.; Begg, F.; Wilkinson, I.; Yarwood, S.; Ackerman, C.; Houslay, E.S.; Hoffman, R.; Engels, P.; Sullivan, M.; Bolger, G. Intracellular targeting, interaction with Src homology 3 (SH3) domains and rolipram-detected conformational switches in cAMP-specific PDE4A phosphodiesterase. Biochem. Soc. Trans., 1997, 25, 374-381.
65. Wachtel, H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors. Neuropharmacology, 1983, 22, 267-272.
66. DaSilva, J.N.; Lourenco, C.M.; Wilson, A.A.; Houle, S. Syntheses of the phosphodiesterase-4 inhibitors [11C]Ro 20-1724, R-, R/Sand S-[11C]rolipram. J. Label. Compd. Radiopharm., 2001, 44, 373-384.
67. 11C]Ro 20-1724 in rats. Synapse, 1999, 31, 41-50.
68. Parker, C.A.; Matthews, J.C.; Gunn, R.N.; Martarello, L.; Cunningham, V.J.; Dommett, D.; Knibb, S.T.; Bender, D.; Jakobsen, S.; Brown, J.; Gee, A.D. Behaviour of [(11)C]R(-)-and [(11)C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4. Synapse, 2005, 55, 270-279.
69. Harada, N.; Nishiyama, S.; Ohba, H.; Sato, K.; Kakiuchi, T.; Tsukada, H. Age differences in phosphodiesterase type-IV and its functional response to dopamine D1 receptor modulation in the living brain: a PET study in conscious monkeys. Synapse, 2002, 44, 139-145.
70. Fujita, M.; Zoghbi, S.S.; Crescenzo, M.S.; Hong, J.; Musachio, J.L.; Lu, J.Q.; Liow, J.S.; Seneca, N.; Tipre, D.N.; Cropley, V.L.; Imaizumi, M.; Gee, A.D.; Seidel, J.; Green, M.V.; Pike, V.W.; Innis, R.B. Quantification of brain phosphodiesterase 4 in rat with (R)-[(11)C]Rolipram-PET. Neuroimage, 2005, 26, 1201-1210.
71. Itoh, T.; Abe, K.; Zoghbi, S.S.; Inoue, O.; Hong, J.; Imaizumi, M.; Pike, V.W.; Innis, R.B.; Fujita, M. PET measurement of the in vivo affinity of 11C-(R)-rolipram and the density of its target, phosphodiesterase-4, in the brains of conscious and anesthetized rats. J. Nucl. Med., 2009, 50, 749-756.
72. Kenk, M.; Greene, M.; Thackeray, J.; Dekemp, R.A.; Lortie, M.; Thorn, S.; Beanlands, R.S.; Dasilva, J.N. In vivo selective binding of (R)-[(11)C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues. Nucl. Med. Biol., 2007, 34, 71-77.
73. Thomas A.J.; Renaud, J.M.; Lortie, M.; Kenk, M.; Beanlands, R.S.; DaSilva, J.N.; deKemp, R.A. In vivo characterization of (R)-[11C]Rolipram PDE4-specific binding in rat heart using small animal PET. J. Nucl. Med., 2011, 52, 263-269.
74. Krause, W.; Kühne, G. Biotransformation of the antidepressant D, L-rolipram. II. Metabolite patterns in man, rat, rabbit, rehesus and cynomolgus monkey. Xenobiotica, 1993, 23, 1277-1288.
75. Krause, W.; Kühne, G.; Matthes, H. Pharmacokinetics of the antidepressant rolipram in healthy volunteers. Xenobiotica, 1989, 19, 683-692.
76. Lortie, M.; DaSilva, J.; Kenk, M.; Thorn, S.; Beanlands, R.; deKemp, R. Kinetics of (R)-[11C]Rolipram and (S)-[11C]Rolipram in the Dog Heart: Investigation of Four Compartment Models. IEEE Medical Imaging Conference. San Diego, California, 2006, p. A274.
77. Lourenco, C.M.; Houle, S.; Wilson, A.A.; DaSilva, J.N. Characterization of (R)-[11C]rolipram for PET imaging of phosphodiesterase-4: in vivo binding, metabolism, and dosimetry studies in rats. Nucl. Med. Biol., 2001, 28, 347-358.
78. Gee, A.; Parker, C.; Matthews, J.; Passchier, J.; Smith, D.; Bender, D.; Knibb, S.; Gjedde, A.; Brown, J. Evidence to support the use of S(+)-[11C]Rolipram in estimating the non-specific binding componentof R(-)-[11C]Rolipram to PDE4 in vivo using PET. Neuroimage, 2002, 16, S34.
79. Corona, G.; Mondaini, N.; Ungar, A.; Razzoli, E.; Rossi, A.; Fusco, F. Phosphodiesterase Type 5 (PDE5) Inhibitors in Erectile Dysfunction: The Proper Drug for the Proper Patient. J. Sex. Med., 2011, 8, 3418-3432.
80. Jackson, G.; Gillies, H.; Osterloh, I. Past, present, and future: a 7-year update of Viagra (sildenafil citrate). Int. J. Clin. Pract., 2005, 59, 680-691.
81. Sastry, B.K.; Narasimhan, C.; Reddy, N.K.; Raju, B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol., 2004, 43, 1149-1153.
82. Cvelich, R.G.; Roberts, S.C.; Brown, J.N. Phosphodiesterase Type 5 Inhibitors as Adjunctive Therapy in the Management of Systolic Heart Failure. Ann. Pharmacother., 2011 Nov 24 [Epub ahead of print].
83. Vlachopoulos, C.; Terentes-Printzios, D.; Ioakeimidis, N.; Rokkas, K.; Stefanadis, C. PDE5 inhibitors in non-urological conditions. Curr. Pharm. Des., 2009, 15, 3521-3539.
84. Bell, A.S.; Palmer, M.J. Novel phosphodiesterase type 5 modulators: a patent survey (2008-2010). Expert Opin. Ther. Pat., 2011, 21, 1631-1641.
85. 11C]RAL-01, a potential phosphodiesterase 5 radioligand. Nucl. Med. Biol., 2006, 33, 593-597.
86. Chekol, R.; Gheysens, O.; Cleynhens, J.; Janssens, S.; Verbruggen, A.; Bormans. G. Radiosynthesis and biological evaluation of a carbon-11 labelled vardenafil derivative as a PDE5 specific tracer. J. Label. Compds. Radiopharm., 2011, 54, S152.
87. Chekol, R.; Gheysens, O.; Cleynhens, J.; Janssens, S.; Verbruggen, A.; Bormans. G. Radiosynthesis and biological evaluation of a carbon-11 labelled vardenafil derivative as a PDE5 specific tracer. J. Label. Compds. Radiopharm., 2011, 54, S153.
88. Bi, Y.; Stoy, P.; Adam, L.; He, B.; Krupinski, J.; Normandin, D.; Pongrac, R.; Seliger, L.; Watson, A.; Macor, J.E. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. Bioorg. Med. Chem. Lett., 2004, 14, 1577-1580.
89. Pokreisz, P.; Vandenwijngaert, S.; Bito, V.; Van den Bergh, A.; Lenaerts, I.; Busch, C.; Marsboom, G.; Gheysens, O.; Vermeersch, P.; Biesman, L.; Liu, X.; Gillijns, H.; Pellens, M.; Van Lommel, A.; Buys, E.; Schoonjans, L.; Vanhaecke, J.; Verbeken, E.; Sipido, K.; Herijgers, P.; Bloch, K.D.; Janssens, S.P. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation, 2009, 119, 408-416.
90. Kehler, J.; Ritzén, A.; Rodriguez Greve, D. The potential therapeutic use of phosphodiesterase 10 inhibitors. Expert Opin. Ther. Patents, 2007, 17, 147-158.
91. Siuciak, J.A.; McCarthy, S.A.; Chapin, D.S.; Fujiwara, R.A.; James, L.C.; Williams, R.D.; Stock, J.L.; McNeish, J.D.; Strick, C.; Menniti, F.S.; Schmidt, C.J. Genetic deletion of the striatum enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuopharmacology, 2006, 51, 374-385.
92. Siuciak, J.A.; McCarthy, S.A.; Chapin, D.; Martin, A.N.; Harms, J.F.; Schmidt, C.J. Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/B16N congenic background. Neuropharmacology, 2008, 54, 417-427.
93. Giorgi, M.; Melchiorri, G.; Nuccetelli, V.; D'Angelo, V.; Martorana, A.; Sorge, R.; Castelli, V.; Bernardi, G.; Sancesario, G. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology. Neurobiol. Dis., 2011, 43, 293-303.
94. Siuciak, J.A.; Chapin, D.S.; Harms, J.F.; Lebel, L.A.; McCarthy, S.A.; Chambers, L.; Shrikhande, A.; Wong, S.; Menniti, F.S.; Schmidt, C.J. Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis. Neuropharmacology, 2006, 51, 386-396.
95. Grauer, S.M.; Pulito, V.L.; Navarra, R.L.; Rachel, L.; Kelly, M.P.; Kelley, C.; Graf, R.; Langen, B.; Logue, S.; Brennan, J.; Jiang, L.; Charych, E.; Egerland, U.; Liu, F.; Marquis, K.L.; Malamas, M.; Hage, T.; Comery, T.A.; Brandon, N. J. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J. Pharmacol. Exp. Ther., 2009, 331, 574-590.
96. Giampà, C.; Patassini, S.; Borreca, A.; Laurenti, D.; Marullo, F.; Bernardi, G.; Menniti, F.S.; Fusco, F.R. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiol. Dis., 2009, 34, 450-456.
97. Giampà, C.; Laurenti, D.; Anzilotti, S.; Bernardi, G.; Menniti, F.S.; Fusco, F.R. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One, 2010, 5, e13417.
98. Tu, Z.; Xu, J.; Jones, L.A.; Li, S.; Mach, R.H. Carbon-11 Labeled Papaverine as a PET Tracer for Imaging PDE10A: Radiosynthesis, In Vitro and In Vivo Evaluation. Nucl. Med. Biol., 2010, 37, 509-516.
99. Belpaire, F.M.; Bogaert, M.G. Metabolism of papaverine. II. Species differences. Xenobiotica, 1975, 5, 421-429.
100. Verhoest, P.R.; Chapin, D.S.; Corman, M.; Fonseca, K.; Harms, J.F.; Hou, X.; Marr, E.S.; Menniti F.S.; Nelson, F.; O'Connor, R.; Pandit, J.; Proulx-LaFrance, C.; Schmidt, A.W.; Schmidt, C J.; Suiciak, J.A.; Liras, S. Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia. J. Med. Chem., 2009, 52, 5188-5196.
101. 11C]-MP10 and its regio-isomer as potential radioligands for positron emission tomography imaging of phosphodieasterase-10A in the brain. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, S206.
102. 18F]-isoJNJ41510417 as potential radioligands for positron emission tomography imaging of phosphodieasterase-10A in the brain. J. Label. Compd. Radiopharm., 2011, 54, S576.
103. 11C]MP-10 as a PET probe for imaging PDE10A in rodent and nonhuman primate brain. Bioorg. Med. Chem., 2011, 19, 1666-1673.
104. 11C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. Nucl. Med. Biol., 2011, 38, 875-884.
105. Andrés-Gil, J. I.; Bormans, G. M.; De Angelis, M.; Celen, S. Radiolabelled PDE10 Ligands. PCT Int. Appl. WO2010097367, September 2, 2010.
106. 18F-JNJ41510417 as a Radioligand for PET Imaging of Phosphodiesterase-10A in the Brain. J. Nucl. Med., 2010, 51, 1584-1591.
107. Laruelle, M.; Slifstein, M.; Huang, Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol. Imaging Biol., 2003, 5, 363-375.
108. Pike, V. W. PET Radiotracers: Crossing the Blood-Brain Barrier and Surviving Metabolism. Trends Pharmacol. Sci., 2009, 30, 431-440.
109. Andrés-Gil, J. I.; De Angelis, M.; Bormans, G. M.; Celen, S. Radiolabelled PDE10 Ligands. PCT Int. Appl. WO2011051324, May 5, 2011.
110. Andrés, J. I.; De Angelis, M.; Alcazar, J.; Iturrino, L.; Langlois, X.; Dedeurwaerdere, S.; Lenaerts, I.; Vanhoof, G.; Celen, S.; Bormans, G. Synthesis, In Vivo Occupancy and Radiolabeling of Potent Phosphodiesterase Subtype-10 Inhibitors as candidates for Positron Emission Tomography Imaging. J. Med. Chem., 2011, 54, 5820-5835.
111. 18F]fluoroethoxy)-6-methoxyquinazoline derivative for imaging PDE10A with PET. J. Label. Compd. Radiopharm., 2011, 54, S268.